Features of the evaluation of the clinical efficacy of treatment of vulvovaginitis in girls (clinical case)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Vulvovaginitis (VV) ranks first in the structure of gynecological diseases of girls and adolescents. This is primarily due to the anatomical features of the structure of children’s genital organs; in addition, alkaline reaction of vaginal secretion, low glycogen content, the absence of Doderlein bacilli, low estrogen level and low immune resistance contribute to the penetration of pathogenic causative agents, leading to the VV occurrence. Description of the clinical case. A clinical case of VV in a 3-year-old girl is described. A local anti-inflammatory therapy with the drug benzydamine (Tantum® Rosa) was carried out 2 times a day for 7 days. Conclusion. Based on the results of the child’s treatment, it has been shown that Tantum® Rosa is one of the effective drugs for treating girls with VV caused by coliform bacteria and streptococci, as well as Candida fungi. The use of this drug in girls and adolescents is recommended in both outpatient and home settings in accordance with the instructions under the supervision of a specialist.

Full Text

Restricted Access

About the authors

Elena V. Sibirskaya

A.I. Yevdokimov MSUMD; Morozov Children's City Clinical Hospital

Department of Reproductive Medicine and Surgery FAPE

G. M Turgunova

Morozov Children's City Clinical Hospital

MD, Chief specialist gynecologist of children and youth in Moscow, obstetrician-gynecologist of the highest qualification category, prof. at the Department of Reproductive Medicine and Surgery; Head at the Department of Gynecology

References

  1. Адамян Л.В., Сибирская Е.В., Глыбина Т.М., Богданова Е.А. Инфекционно-воспалительные заболевания гениталий у детей и подростков. Акушерство и гинекология. 2012;4-1:108-12.
  2. Адамян Л.В., Сибирская Е.В., Котунов И.Е. и др. Вульвовагинит у девочек в препубертатном и пубертатном периодах развития (обзор литературы). 2018;3:1025-7217.
  3. Бансова Б.И., Бижанова Д.А., Богинская Л.Н. Гинекология. М., 2014.
  4. Кириллова Е.Н., Павлюкова С.А., Акулич Н.С. Вульвовагинит у детей. Медицинский журнал. 2017;2(60):151-3.
  5. Косых С.Л., Мозес В.Г. Диагностика и лечение вульвовагинитов у девочек. Мать и Дитя в Кузбассе. 2012;4(51):3-6.
  6. Хурасева А.Б. Факторы риска персистенции вульвовагинита у девочек и оптимизация терапии. Репродуктивное здоровье детей и подростков. 2014;3:45-50.
  7. Zuckerman A., Romano M. Clinical recommendation: Vulvovaginitis. J. Pediatr Adolesc Gynecol. 2016;29(6):673-79. Doi: https://doi. org/10.1016/j.jpag.2016.08.002-8.
  8. Loveless M., Myint O. Vulvovaginitis - presrntation of more common problems in pediatric and adolescent gynecology. Best Practice and Research. Clin Obstetr Gynae Col. 2017;1521-6934(17):30132-3. Doi: https://doi. org/10.1016/j.bpobgyn.2017.08.014.
  9. Gemek F., Odabaş D., Şenel Ü., Kocaman A.T. Personal Hygiene and Vulvovaginitis in Prepubertal Children. J Pediatr Adol Gynecol. 2016;29(3):223-27. Doi: https://doi.org/10.1016/j.jpag.2015.07.002.
  10. Bumbuliene Z., Venelaviciute K., Ramasanskaite D. Microbiologycal finding of vulvovaginitis in prepubertal girls. Postgraduate Med J. 2014;90( 1059):8-12. Doi: https://doi. org/10.1136/postgradmedj-2013-131959.
  11. Sharifynia S., Falahati M., Akhlaghi L., et al. Molecular identification and antifungal susceptibility profile of Candida species isolated from patients with vulvovaginitis in Tehran, Iran. J Res Med Sci. 2017;22;132. Doi: https: // doi: 10.4103/jrms.JRMS_106_17.
  12. Czajka R., et al. Assessment of the efficacy of benzydamine (Tantum Rosa) in form of vaginal lavage in the treatment of perineal complaints in the early puerperium. Pol J Gyn Invest. 2001;4(2):99-105.
  13. Fisher D.J. Pediatric Urinary Tract Infection Treatment & Management. URL: http://emedicine. medscape.com/article/969643-overview. Accessed on 20 June 2014.
  14. Magliano E., et al. The role of benzydamine in the topical treatment of the so-called nonspecific vaginitis. Int J Tiss React. 1987;X1(2):151-56.
  15. Naber K.G. Efficacy and safety of the phytotherapeutic drug Canephron® N in prevention and treatment of urogenital and gestational disease: review of clinical experience in Eastern Europe and Central Asia. Res Rep Urol. 2013;5:39 46
  16. Quane P.A., Graham G.G., Ziegler J.B. Pharmacology of benzydamine. Inflammopharmacol. 1998;6(2):95-107
  17. Слукин П.В., Фурсова Н.К., Брико Н.И. Антибактериальная активность бензидамина гидрохлорида против клинических изолятов бактерий, выделенных от людей в России и Испании. Эпидемиология и вакцинопрофилактика. 2018;6
  18. Порядин Г. В., Салмаси Ж.М., Казимирский А.Н. Механизм действия бензидамина на локальное воспаление. Медицинский совет 2018;21:72-80

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies